CXCL9 and melanoma: Using mouse melanoma and breast tumor models, we found that PU.1 inhibition by DB suppressed tumor growth, likely through promoting CXCL9 expression in TAMs, which enhances the tumor infiltration of lymphocytes, including CD4+ Th1, CD8+ cytotoxic T lymphocytes (CTLs), and NK cells.